Henry Ford Health

Henry Ford Health Scholarly Commons
Nephrology Articles

Nephrology

1-1-2014

Kidney failure: Cardiorenal and venorenal
Jerry Yee
Henry Ford Health, JYEE1@hfhs.org

Follow this and additional works at: https://scholarlycommons.henryford.com/nephrology_articles

Recommended Citation
Yee J. Kidney failure: Cardiorenal and venorenal. Advances in Chronic Kidney Disease 2014;
21(6):453-455.

This Article is brought to you for free and open access by the Nephrology at Henry Ford Health Scholarly
Commons. It has been accepted for inclusion in Nephrology Articles by an authorized administrator of Henry Ford
Health Scholarly Commons.

Ackd
Advances in Chronic Kidney Disease

Vol 21, No 6, November 2014

EDITORIAL

Kidney Failure: Cardiorenal and Venorenal

T

his issue of Advances in Chronic Kidney Disease is guestedited by John P. Middleton and Uptal Patel. It is a
timely one and is focused on the hope that CKD and cardiovascular disease (CVD) providers can collaborate
with and learn from each other. CVD is rampant among
patients with CKD. Patients with heart failure, valvular
disorders, and arrhythmic disorders occupy signiﬁcant
space in the realm of CKD. The concomitance of cardiac
and kidney disease has led to the nosology of cardiorenal
syndrome that conveys the kidney as victim, types 1 and 3,
and perpetrator of the syndrome, types 2 and 4.1 Needless
to say, coherent and cohesive collaboration between kidney and heart physicians is an absolute necessity to optimize treatment for patients with both CKD and CVD.
Systolic cardiac failure is marked by supranormal neurohormonal activation. Tremendous elevations of catecholamines were detected by Cohn and colleagues2 in
individuals with severely depressed left ventricular (LV)
ejection fractions. These elevations of catecholamines are
accompanied by a highly activated renin-angiotensinaldosterone system, which led the kidney toward untoward
effects, sodium retention and increased peripheral vascular
resistance that increased blood pressure and aggravated
left ventricular impedance, with resultant congestion. As
well, this pathophysiology is synergized by the deleterious
effects of hypercatecholaminemia on cardiomyocytes.
Conversely, in CKD, there is enhanced sympathoadrenal
activity, which may aggravate heart failure by the same
mechanisms.
Classically, individuals with left ventricular failure and
forward output failure, especially when acute and severe,
develop acute kidney injury. This scenario occurs in approximately 27% to 42% of cases of acute cardiac insufﬁciency.1
In fact, the greater the increment in serum creatinine, the
more severe the heart failure. Valvular disorders on the
left side of the heart are also associated with azotemia, an
ominous sign. As left ventricular function declined, the
nephrologist is often consulted for enhancement of a failing
diuretic regimen coinciding with a rising serum creatinine,
the strategy essentially one of left ventricular unloading
with restoration of the ventricle’s pressure-volume relationships to a more optimal circumstance. Yet diuretic therapy is
often not optimized for fear of “overdiuresis” with consequent hypotension.3

Nearly every hospital, medical group, or health care system (including my own) employs some sort of protocol for
their heart failure patients that includes sodium restriction, medication adherence, and daily bodyweight readings.4 But how many protocols actually optimize
diuretic therapy or defer decision-making to an “expert?”
Likely few. Moreover, the Joint Commission on Accreditation of Healthcare Organizations quality of care indicators
for heart failure do not explicitly mandate an assessment
of kidney function, only LV function.5 The employment
of combination diuretic therapy is underused, and combination treatment can often break through diuretic resistance. For example, using a high dose of thiazide-type
diuretic or a loop agent with a mineralocorticoid receptor
antagonist (MRA) would augment diuresis and attenuate
the anticipated hyperkalemia from the latter agent.6
Although, using an MRA in patients with depressed LV
function, as delineated by the Randomized Aldactone
Evaluation Study (RALES)7 and Eplerenone Post-Acute
Myocardial Infarction Heart Failure Efﬁcacy and Survival
Study (EPHESUS),8 have clearly provided an improvement in CV end points, there is often avoidance of
MRAs whenever there is concomitant CKD, in part
because of an apprehension of inducing hyperkalemia.9
The latter ﬁnding was less common in blacks compared
with nonblacks who participated in RALES, but nonblacks comprised 93% of participants, and 87% of participants treated with spironolactone were white.7,10
Presumably, hyperkalemia may be sidestepped in heart
failure altogether by avoiding angiotensin-converting
enzyme inhibitors (ACEIs) and angiotensin 2 receptor
blockers (ARBs), in favor of isosorbide dinitrate and hydralazine compounds. The latter, compounded as a ﬁxed dose
combination, received a race-based recommendation in
heart failure patients in the African American population,
the population most vulnerable to CKD. This recommendation was based on a retrospective analysis of Vasodilator
Heart Failure Trial (V-HeFT) II, which demonstrated a
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superior effect on 2-year mortality of nitrate-hydralazine
over enalapril/placebo in African Americans.
The results of the V-HeFT I and II studies in which blacks
constituted just 27% of the participants, plus an analysis of
Studies of Left Ventricular Dysfunction (SOLVD) in which
blacks only constituted 12% of the participants, demonstrated that black participants fared better with a
nitrate-hydralazine regimen, whereas white participants
fared better with ACE inhibition. Quite notably in
SOLVD, enalapril therapy in whites was associated with
only a modest blood pressure reduction after 1 year, 5.0/
3.6 mm Hg.11 The results of these trials fundamentally
improved the care of heart failure, but they had the unintended consequence of denying important aspects of care
to heart failure patients with CKD. Essentially, black CKD
patients with heart failure can be treated with ACEIs or
ARBs to attenuate CKD progression and white patients
with heart failure and CKD may be treated with nitrates
and hydralazine, if intolerant to ACEI or ARB treatment.
In addition, the Beta-Blocker Evaluation of Survival Trial
(BEST) determined that black patients did not beneﬁt
from bucindolol treatment, whereas whites did.12 Nonetheless, beta-blocker therapy in white CKD patients with
heart failure is underemphasized. Lastly, the induction
of hyperkalemia using ACEI/ARB therapy can be offset
in most instances by dietary restriction of potassium and
diuretic therapy.
In heart failure patients, the optimal blood pressure ﬂoor
has not been established: “How low should you go?” The
dictum has generally been to lower blood pressure as
much as possible because this reduces impedance to left
ventricular output—the cardiocentric view. Contrariwise,
the kidneys may now reside at a subthreshold level of
ischemia where any further renal insult(s) can induce an
episode of acute kidney injury (AKI)—the nephrocentric
view. AKI often occurs in the face of normal blood pressure,13 particularly when there is predisposing CKD
with its right-shifted, sodium-pressure sigmoidal curve.14
A mean arterial pressure of 60 mm Hg does not necessarily equate to adequate renal perfusion in man as it
does in rats whose vascular trees have not been damaged
by hypercholesterolemia, smoking, or aging. Lastly, the
primary care physician may note that the patient is symptomatically hypotensive—the Internal Medicine view.
Guidance here is critical and will require collaborative
trials between cardiologists and nephrologists. This is
especially true since the 2013 publication of the American
Heart Association’s blood pressure guideline15 that has redeﬁned the blood pressure thresholds for hypertension in
diabetes and CKD. A comprehensive evaluation of highquality observational and retrospective analyses of heart
failure patients with CKD (and vice versa) must be
done, and these can inform the basis of randomized,
controlled studies that should be designed and implemented by a team of kidney failure and heart failure
collaborator-investigator groups.
The importance of right-sided heart failure in CKD has
been emphasized recently. Not all patients with CKD
and heart failure manifest impaired LV ejection fractions
of less than 25% to 30%. These patients typically manifest
LV diastolic dysfunction with preserved LV ejection frac-

tion and cardiac output at the expense of elevated left
ventricular end-diastolic pressure. This circumstance is
seen in 40% to 50% of patients with congestive failure.
Consequently, the pulmonary artery wedge pressure is
elevated, which is transmitted in retrograde fashion to
the renal veins. This augmented renal venous pressure is
central to the pathogenesis of CKD.
Irving H. Page tightly enveloped the rat kidney in cellophane to produce an encasing ﬁbrocollagenous hull, and
the concept of kidney compression as causative of AKI
was born.16,17 Since his original description, kidney
failure in man from a “Page” kidney has been recounted
in numerous circumstances, often with the compression
by a subcapsular or perinephric hematoma. However,
the importance accorded to tissue compression may
have masked the true underlying pathophysiological
mechanism inherent to the Page kidney. Recently,
investigators, in a carefully done, experimental, swine
model, demonstrated that the decline in glomerular
ﬁltration was independent of organ compression but
dependent on renal vein pressure. Higher renal venous
pressure was negatively correlated with rat inulin
clearance. Another group has forwarded the hypothesis
that interstitial inﬂammation is the inciting mechanism
or, at a minimum, contributory.18
The Page kidney’s wrapping included the hilum and
likely increased renal venous pressure although this
was not reported in Page’s original report. Expanding
the concept of increased renal venous pressure as the
cause of depressed glomerular ﬁltration uniﬁes the kidney failure associated with multiple other etiologies in
which no parenchymal disorder had been previously established. Several of these include the abdominal
compartment syndrome, bilateral renal vein thrombosis,
inferior vena cava (IVC) thrombosis, and many cardiopulmonary disorders characterized by high central
venous pressures or pulmonary artery pressures. In
each of these problems, there is elevated renal venous
pressure, the renal consequences of which are elevated
plasma renin activity, increased aldosterone, hypertension, loss of autoregulation, and diminished glomerular
ﬁltration rate.19,20
Importantly, in the abdominal compartment syndrome,
the pressure on the renal vein is not linearly related with
volume of ascites. A more complicated pressure-volume
relationship exists that does not follow Boyle’s law—
namely, that pressure is not inversely related to volume
in linear fashion. However, akin to cardiac tamponade
from pericardial effusion, removal of a relatively small
volume of ﬂuid can rapidly lead to an improvement of
renal function. Ironically, large-volume paracentesis
frequently is associated with delayed AKI, despite an
improvement in the overall hemodynamic proﬁle.21
Notably, IVC thrombosis, bilateral renal vein thrombosis,
and cardiopulmonary disorders are also characterized by
elevated renal venous pressures.
Whether the CKD associated with obesity is aggravated
by elevated renal vein pressure is unknown; however,
adipose tissue-induced venous compression manifested
by lower extremity edema reﬂects elevated IVC pressure.
The notion that reduced glomerular ﬁltration attributable
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to high renal venous pressure in obesity complicates
obesity-related glomerulopathy (ORG)22 has substantial
credence because the relatively rapid improvement in
kidney function associated with weight loss would not
be attributed to the repair of ORG-related lesions
that had resulted from glomerular hyperﬁltration. In
addition, weight loss attenuates the marked elevations
of plasma renin and aldosterone that are associated with
this disorder.
In addition, does the obstructive sleep apnea that is
prevalent among morbidly obese individuals perpetuate
or initiate kidney failure? This hypothesis may be substantiated when secondary pulmonary hypertension is present and leads to elevated renal vein pressure. Acute
elevations of pulmonary arterial hypertension in patients
with exacerbations of chronic obstructive pulmonary disease explain in part the appearance of AKI. Hypoxiainduced increases in pulmonary artery pressures reduce
left ventricular ﬁlling pressures dependent on an already
impaired right ventricle. Right ventricular dysfunction
consequently elevates central venous pressure that is reﬂected in the renal veins with consequent depression of
glomerular ﬁltration. Here, oxygen, not a loop diuretic,
is reparative.
Taken collectively, heart failure, with or without congestive symptoms and left- or right-sided, produces a cardiorenal syndrome that demands an integrated and
collaborative care model that involves cardiologists and
nephrologists. The more recently exempliﬁed venorenal
syndromes will also require coordinated care between nephrologists and less familiar partners, including hepatologists, bariatric specialists, and pulmonary hypertension
physicians. This should not prove difﬁcult as CKD has
become the new nexus of care of in Internal Medicine
and Family Medicine. Certainly, we have surpassed the
conventional and passive model of severe left ventricular
depression as the sole cause of cardiorenal failure.
Jerry Yee, MD
Editor-in-Chief
Detroit, MI
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